Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remdesivir for the Treatment of Covid-19 — Final Report
John H. Beigel, Kay M Tomashek, Lori E. Dodd, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 19, pp. 1813-1826
Open Access | Times Cited: 7135

Showing 1-25 of 7135 citing articles:

Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby, Wei Shen Lim, Jonathan Emberson, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 8, pp. 693-704
Open Access | Times Cited: 7610
Characteristics of SARS-CoV-2 and COVID-19
Ben Hu, Hua Guo, Peng Zhou, et al.
Nature Reviews Microbiology (2020) Vol. 19, Iss. 3, pp. 141-154
Open Access | Times Cited: 4749
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
W. Joost Wiersinga, Andrew Rhodes, Allen C. Cheng, et al.
JAMA (2020) Vol. 324, Iss. 8, pp. 782-782
Closed Access | Times Cited: 4342
Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan, José Mateus, Yu Kato, et al.
Science (2021) Vol. 371, Iss. 6529
Open Access | Times Cited: 2727
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
Hongchao Pan, Richárd Pető, Ana‐Maria Henao‐Restrepo, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 6, pp. 497-511
Open Access | Times Cited: 2497
Mechanisms of SARS-CoV-2 entry into cells
Cody B. Jackson, Michael Farzan, Bing Chen, et al.
Nature Reviews Molecular Cell Biology (2021) Vol. 23, Iss. 1, pp. 3-20
Open Access | Times Cited: 2410
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Takuya Sekine, André Perez‐Potti, Olga Rivera‐Ballesteros, et al.
Cell (2020) Vol. 183, Iss. 1, pp. 158-168.e14
Open Access | Times Cited: 1839
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
Carolyn Rydyznski Moderbacher, Sydney I. Ramirez, Jennifer M. Dan, et al.
Cell (2020) Vol. 183, Iss. 4, pp. 996-1012.e19
Open Access | Times Cited: 1793
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
André C. Kalil, Thomas F. Patterson, Aneesh K. Mehta, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 9, pp. 795-807
Open Access | Times Cited: 1681
Remdesivir for the Treatment of Covid-19 — Preliminary Report
James McMahon, Andrew Udy, Anton Y. Peleg
New England Journal of Medicine (2020) Vol. 383, Iss. 10, pp. 992-994
Open Access | Times Cited: 1430
Severe Covid-19
David Berlin, Roy M. Gulick, Fernando J. Martínez
New England Journal of Medicine (2020) Vol. 383, Iss. 25, pp. 2451-2460
Closed Access | Times Cited: 1390
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman, David Chien Lye, David S.C. Hui, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 19, pp. 1827-1837
Open Access | Times Cited: 1381
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen, Ajay Nirula, Barry N. Heller, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 3, pp. 229-237
Open Access | Times Cited: 1347
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone, Matthew J. Frigault, Naomi Serling‐Boyd, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 24, pp. 2333-2344
Open Access | Times Cited: 1311
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Masataka Nishiga, Dao Wen Wang, Yaling Han, et al.
Nature Reviews Cardiology (2020) Vol. 17, Iss. 9, pp. 543-558
Open Access | Times Cited: 1303
Mild or Moderate Covid-19
Rajesh T. Gandhi, John B. Lynch, Carlos del Rı́o
New England Journal of Medicine (2020) Vol. 383, Iss. 18, pp. 1757-1766
Closed Access | Times Cited: 1274
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
Christoph D. Spinner, Robert Gottlieb, Gerard J. Criner, et al.
JAMA (2020) Vol. 324, Iss. 11, pp. 1048-1048
Open Access | Times Cited: 1177
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Alexandre Biasi Cavalcanti, Fernando G Zampieri, Régis Goulart Rosa, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 21, pp. 2041-2052
Open Access | Times Cited: 1072
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
Thomas Mandel Clausen, Daniel R. Sandoval, Charlotte B. Spliid, et al.
Cell (2020) Vol. 183, Iss. 4, pp. 1043-1057.e15
Open Access | Times Cited: 1047
A living WHO guideline on drugs for covid-19
Arnav Agarwal, Beverley J. Hunt, Miriam Stegemann, et al.
BMJ (2020), pp. m3379-m3379
Open Access | Times Cited: 962
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Iván O. Rosas, Norbert Bräu, Michael R. Waters, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 16, pp. 1503-1516
Open Access | Times Cited: 953
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon, et al.
Nature Reviews Endocrinology (2020) Vol. 17, Iss. 1, pp. 11-30
Open Access | Times Cited: 925
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Ventura Simonovich, Leandro Daniel Burgos Pratx, Paula Scibona, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 7, pp. 619-629
Open Access | Times Cited: 908
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
Robert Gottlieb, Ajay Nirula, Peter Chen, et al.
JAMA (2021) Vol. 325, Iss. 7, pp. 632-632
Open Access | Times Cited: 884
Page 1 - Next Page

Scroll to top